BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38009626)

  • 21. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
    Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
    Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples.
    Song F; Du H; Wang C; Huang X; Wu R;
    PLoS One; 2020; 15(6):e0234518. PubMed ID: 32525936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping.
    Hernández-López R; Lorincz AT; Torres-Ibarra L; Reuter C; Scibior-Bentkowska D; Warman R; Nedjai B; Mendiola-Pastrana I; León-Maldonado L; Rivera-Paredez B; Ramírez-Palacios P; Lazcano-Ponce E; Cuzick J; Salmerón J;
    Clin Epigenetics; 2019 Oct; 11(1):140. PubMed ID: 31606044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of p16/Ki-67 dual staining in the detection of cervical precancer and cancer in China.
    Zhang SK; Jia MM; Zhao DM; Wu ZN; Guo Z; Liu YL; Guo PP; Chen Q; Cao XQ; Liu SZ; Chen W; Sun XB
    Cancer Epidemiol; 2019 Apr; 59():123-128. PubMed ID: 30739069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.
    Wentzensen N; Clarke MA; Bremer R; Poitras N; Tokugawa D; Goldhoff PE; Castle PE; Schiffman M; Kingery JD; Grewal KK; Locke A; Kinney W; Lorey TS
    JAMA Intern Med; 2019 Jul; 179(7):881-888. PubMed ID: 31081870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
    Wentzensen N; Schwartz L; Zuna RE; Smith K; Mathews C; Gold MA; Allen RA; Zhang R; Dunn ST; Walker JL; Schiffman M
    Clin Cancer Res; 2012 Aug; 18(15):4154-62. PubMed ID: 22675168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between P16/Ki67 in cervical cytology and diagnosis of cervical intraepithelial neoplasia 2-3 in Thai women infected with high-risk types of human papillomavirus.
    Srisuttayasathien M; Kantathavorn N; Luasiripanthu T; Petchjorm S; Samrarn J; Ittiamornlert P; Krisorakun W; Vanichtantikul A; Wetcho T; Saeloo S
    Taiwan J Obstet Gynecol; 2024 Mar; 63(2):192-198. PubMed ID: 38485314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA methylation testing with S5 for triage of high-risk HPV positive women.
    Adcock R; Nedjai B; Lorincz AT; Scibior-Bentkowska D; Banwait R; Torrez-Martinez N; Robertson M; Cuzick J; Wheeler CM;
    Int J Cancer; 2022 Oct; 151(7):993-1004. PubMed ID: 35477862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triaging HPV-Positive Cervical Samples with p16 and Ki-67 Dual Stained Cytology within an Organized Screening Program-A Prospective Observational Study from Western Norway.
    Øvestad IT; Dalen I; Andersland MS; Vintermyr OK; Moltu P; Berland JM; Janssen EAM; Haugland HK
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
    Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
    J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk stratification for cervical precancer and cancer by DH3-HPV partial genotyping and cytology in women attending cervical screening: A retrospective cohort study.
    Fu Y; Li Y; Li X; Wang X; Lü W
    J Med Virol; 2023 Feb; 95(2):e28482. PubMed ID: 36609841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of high-risk HPV-positive women for detection of cervical (pre)cancer.
    Luttmer R; De Strooper LM; Steenbergen RD; Berkhof J; Snijders PJ; Heideman DA; Meijer CJ
    Expert Rev Mol Diagn; 2016 Sep; 16(9):961-74. PubMed ID: 27459506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Utility of CINtec PLUS Triage in Equivocal Cervical Cytology and Human Papillomavirus Primary Screening.
    McMenamin M; McKenna M; McDowell A
    Am J Clin Pathol; 2018 Oct; 150(6):512-521. PubMed ID: 30169728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study.
    Gilbert L; Ratnam S; Jang D; Alaghehbandan R; Schell M; Needle R; Ecobichon-Morris A; Wadhawan A; Costescu D; Elit L; Wang P; Zahariadis G; Chernesky M
    Cancer Biomark; 2022; 34(3):347-358. PubMed ID: 35001877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.
    Hanley SJB; Fujita H; Aoyama-Kikawa S; Kasamo M; Torigoe T; Matsuno Y; Noriaki S;
    J Gynecol Oncol; 2021 Nov; 32(6):e86. PubMed ID: 34708593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is Primary HPV with Secondary p16/Ki67 Dual-Stain an Alternative HSIL-Risk Detection Strategy in Cervical Cancer Screening for Women under 30 Years?
    Trzeszcz M; Mazurec M; Jach R; Mazurec K; Jach Z; Kotkowska-Szeps I; Kania M; Wantuchowicz M; Prokopyk A; Barcikowski P; Przybylski M; Wach J; Halon A
    Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should we use risk selection tests for HPV 16 and/or 18 positive cases: Comparison of p16/Ki67 and cytology.
    Mazurec K; Trzeszcz M; Mazurec M; Streb J; Halon A; Jach R
    J Med Virol; 2024 Mar; 96(3):e29500. PubMed ID: 38440951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of p16
    Song F; Belinson JL; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    Gynecol Oncol; 2021 Aug; 162(2):322-330. PubMed ID: 34059349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.